Liver Cancer

Patients with unresectable hepatocellular carcinoma experienced an improvement in several health-related quality of life measures following treatment with first-line tislelizumab compared with sorafenib.

Lenvatinib in combination with blank-microsphere transarterial chemembolization and sequential microwave ablation demonstrates encouraging preliminary activity in patients with hepatocellular carcinoma.

Envafolimab in combination with lenvatinib and transarterial chemoembolization demonstrated efficacy and safety among patients with unresectable hepatocellular carcinoma.

Findings from the phase 3 HIMALAYA trial indicate that durvalumab with or without tremelimumab remained efficacious regardless of the presence of anti-drug antibodies in unresectable hepatocellular carcinoma.

Durvalumab plus tremelimumab has been recommended for approval in the European Union for treatment of advanced liver and lung cancers.

A regimen consisting of personalized therapeutic cancer vaccine, GNOS-PV02, as well as plasmid-encoded IL-12 and pembrolizumab yielded an overall response rate of 20.9% among evaluable patients with unresectable or metastatic hepatocellular carcinoma.

Patients with hepatocellular carcinoma may benefit from treatment with OTX-2002, a first-in-class epigenomic controller designed to downregulate c-Myc that recently received orphan drug designation from the FDA

Stereotactic body radiation therapy is a new standard of care option for patients with locally advanced hepatocellular carcinoma, according to a presentation on the phase 3 NRG/RTOG 1112 trial assessing sorafenib combined with stereotactic body radiation therapy.

Based on results from the phase 3 HIMALAYA trial, the FDA has approved tremelimumab plus durvalumab in patients with unresectable hepatocellular carcinoma.

The FDA has given orphan drug designation to ET140203 ARTEMIS, an investigational therapy for hepatoblastoma, the safety and potential efficacy of which are being evaluated in the phase 1/2 ARYA-1 and ARYA-2 studies.

Results from the phase 1/2 TAS-120-101 trial lead to the accelerated approval of futibatinib in patients with locally advanced or metastatic cholangiocarcinoma and an FGFR2 gene fusion or rearrangement.

The FDA has granted orphan drug designation to second-line GNS561 following the completion of a phase 1/2a trial evaluating the novel PPT1 inhibitor in liver cancer and cholangiocarcinoma.

Results from the phase 3 RATIONALE-301 trial showed improved overall survival for patients who were given frontline tislelizumab for unresectable hepatocellular carcinoma.

Results from the LEAP-002 trial revealed extended median overall survival with lenvatinib monotherapy in patients with unresectable hepatocullar carcinoma.

Results of a phase 3 study appear to indicate better progression-free and overall survival outcomes with camrelizumab and rivoceranib vs sorafenib in unresectable hepatocellular carcinoma.

Akihiro Ohba, MD, discussed the potential benefits of T-DXd in HER2-expressing biliary tract cancer.

Khaled W. Kabbara, MD, and colleagues, research treatment options for cholangiocarcinoma.

The phase 3 RATIONALE 301 trial examining first-line tislelizumab vs sorafenib in unresectable hepatocellular carcinoma met the primary end point of noninferior overall survival.

Although patients with unresectable hepatocellular carcinoma initially appeared to have survival benefit following treatment with pembrolizumab and lenvatinib vs lenvatinib alone, the findings did not meet statistical significance.

A recent study found patients with hepatoblastoma who had small cell undifferentiated histology did not have worse outcomes than those who did not.

Individuals with nonalcoholic fatty liver disease–related hepatocellular carcinoma were found to have lower rates of surveillance vs other potential causes of disease.

Tremelimumab’s biologics license application was accepted by the FDA and was given priority review, further supporting the use of a single priming dose of anti-CTLA4 plus durvalumab in unresectable hepatocellular carcinoma.

Patients with recurrent hepatocellular carcinoma after liver transplantation were treated with lenvatinib and saw promising efficacy.

Patients with advanced hepatocellular carcinoma achieved notable improvements in survival and responses following treatment with transarterial chemoembolization and lenvatinib.

A safe and tolerable treatment option of transarterial chemoembolization combined with lenvatinib plus sintilimab was given to patients with hepatocellular carcinoma.

Using transarterial chemoembolization, lenvatinib, and PD-1 checkpoint blockade in patients with unresectable advanced hepatocellular carcinoma appears to be a safe and effective option.

A multicenter study found that using lenvatinib for initial treatment helped to increase survival in patients with stage B2 hepatocellular carcinoma.

Patients with advanced hepatocellular carcinoma achieved a statically significant and clinically meaningful survival benefit following treatment with pembrolizumab and best supportive care in the second line.

Patients with unresectable hepatocellular carcinoma received an overall survival benefit following first-line treatment with durvalumab (Imfinzi) and tremelimumab.

FDA fast track designation comes based on overall survival improvements from a phase 1 trial investigating LioCyx-M004 infusions in primary HBV-related hepatocellular carcinoma.